GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will ...

Outrun Therapeutics (“Outrun”), the E3 ligase inhibitor and protein stabilisation specialist, today announces the appointment of Matthew Fyfe as its Chief Scientific Officer. Matthew has over 25 years ...

Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it is advancing into Cohort 7 in a Phase I/IIa dose ...

The National Medical Products Administration (NMPA) in China has approved Sarclisa, an anti-CD38 medicine, in combination with pomalidomide and dexamethasone (Pd) for the treatment of adult patients ...

CNX Therapeutics Limited (“CNX Therapeutics”), a European specialty pharmaceutical company, has announced a strategic licensing deal for Sumatriptan Alginate Film, expanding its portfolio of CNS ...

Frontage Holdings Corporation (SEHK stock code: 1521) announced on January 6 2025 that Dr. Abdul Mutlib has decided to step aside from his current role as CEO of the company to facilitate the ...

Healthcare providers operate in a high-stakes environment where protecting sensitive patient data is critical. With increasing cybersecurity threats and complex compliance requirements, maintaining ...

Offering rewards helps people to stop smoking, with success rates continuing long after incentives have stopped. The new research, led by the University of East Anglia, also explored whether ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through its ...

Bayer today announced topline results of the Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an investigational gadolinium-based contrast agent (GBCA) for use in magnetic ...

TR-1: Standard form for notification of major holdings LONDON, UNITED KINGDOM / ACCESSWIRE / January 13, 2025 / 1. Issuer DetailsISINGB00BP2C3V08Issuer NameGENFLOW BIOSCIENCES PLCUK or Non-UK ...

Company expands sterile fill-finish services, capacity for biologics development and manufacturing, and more pace logo pace ...